Chicago Clearing

Blogs

Millions in Unsellable Inventory Leads to $109 Million Cardinal Health Securities Settlement
May 05, 2023

Case Name: Cardinal Health

Settlement Fund: $109,000,000

Claim Filing Deadline: 7/24/2023

Class Period: 3/2/2015 -- 5/2/2018



In 2015, Cardinal Health purchased medical device manufacturer Cordis from Johnson and Johnson for $1.944 billion. Cardinal assured investors that this expensive purchase would pay off by entering them into the high-margin cardiovascular and stent market.


Plaintiffs allege that Cardinal botched this acquisition by not meeting the logistical demands of selling such devices. "Critically, unlike Cardinal’s other medical supply products," plaintiffs wrote in their complaint, "heart stents and

catheters have strict product expiration dates, which must be closely monitored to comply with regulatory and quality standards." Throughout the class period, plaintiffs allege that Cardinal repeatedly told investors that the incorporation of Cordis was an ongoing success, while in practice they were losing track of this costly inventory.


In their complaint, Plaintiffs claim that "Cordis’s inventory and supply chain platforms were so deficient that [Cardinal] lacked visibility into customer demand and existing inventory levels, particularly with respect to products consigned to third-party vendors overseas. As a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories. As the excess inventory sat on the shelf, products became unsellable and/or expired."


On August 2, 2017, Cardinal's rosy reports began to change when the company reported weak earnings due to "higher-than-planned write-offs for excess inventory." Cardinal Health stock fell 8% that day, from $77.33 per share on August 1, to a $70.99 close on August 2. In the coming months, the bad news kept coming, the stock kept falling, and finally on May 3, 2018, Cardinal admitted "unanticipated disappointing performance from our Cordis business." Plaintiffs claim this news "stunned" financial analysts. Investors weren't happy either, and after a sell-off the stock price fell 21%, from $64.65 on May 2, to a close of $50.80 on May 3.


If you have any questions about this litigation or any of the hundreds of other cases for which we are filing claims, then please give us a call at 312-204-6970.

Written By: Dennis O'Toole

I could go on and on, but bottom line, the fees being charged are much less than what I was spending in house to file and this is just one less thing I have to spend time trying to figure out how to complete on a consistent basis. Dealing with the CCC staff has been a very positive thing.

- National Bank

We were spending countless hours on class action claims before we signed on with CCC in January. Matt Murray and their technical team ensured our data transmission was seamless and secure. We found everyone at CCC to be professional, courteous, and accommodating.

- Savings Bank

Signing with CCC has made a huge difference. Before, it was horrible. We had to print thousands of pieces of paper, invite clients to come in and sit down with us to show them where to find the transactions, how to input them into the Proof of Claim forms. Now it's simple. It’s very nice to be able to tell our client, “You can shred that Proof of Claim form because CCC has it taken care of.

- Registered Investment Advisor

Your client reporting portal and customer service is the reason we chose Chicago Clearing. I send the data on an annual basis to CCC and they take it from there. My clients are protected (if there is a class action, it is getting filed), the Bank is protected (we are meeting our fiduciary obligation by filing the claims).

- Bank

Contact Us

404 South Wells St., Suite 600,
Chicago, IL 60607 – United States
Phone: (312) 204-6970
Email:
info@chicagoclearing.com

About Us

Chicago Clearing Corporation is the
industry leader in class-action services.

2024 © Chicago Clearing Corporation. All rights reserved. Terms and conditions